Weekly Recap: Gilead gets ABI-6250 option and Phase 2 dosing starts

What happened

Assembly Biosciences started a Phase 2 trial of oral hepatitis delta drug ABI-6250, dosing the first two participants in a study planned to enroll about 80. Initial data are expected in Q4 2027. After reviewing results, Gilead can choose to license the drug; doing so would trigger a $90 million fee for Assembly.

Confirmed

Global impact / market context

The trial is a step toward testing whether ABI-6250 may merit further development, but it does not establish that the drug works. If Gilead exercises its option after reviewing results, Assembly would receive a $90 million fee, providing cash tied to a licensing decision.

Analyst inference

The article describes two linked milestones: Phase 2 dosing has begun, while Gilead's licensing choice depends on reviewing the results. Initial data are not expected until Q4 2027, so the potential fee is conditional rather than current revenue.

Analyst inference

What to watch

1. Follow the Phase 2 study's progress toward its planned enrollment of about 80 participants; the article confirms only that the first two have been dosed. Confirmed
2. Look for the initial data expected in Q4 2027, which may inform whether Gilead chooses to license ABI-6250 under its option. Confirmed
3. Watch for Gilead's decision after data review: exercising the option would trigger a $90 million fee for Assembly, while no exercise means no such fee. Analyst inference

Evidence

• Original source link unavailable